Switching of Biological Therapies in Brazilian Patients With Rheumatoid Arthritis | Zendy

Juliana Miranda de Lucena Valim | Zendy; Fernanda Gomes Gonçalves Chaer | Zendy; Fernanda D’Oliveira Guimarães da Silveira | Zendy; Verônica Palmiro da Silva e Lima | Zendy; Branca Dias Batista de Souza | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Switching of Biological Therapies in Brazilian Patients With Rheumatoid Arthritis

Author(s) -

Juliana Miranda de Lucena Valim,

Fernanda Gomes Gonçalves Chaer,

Fernanda D’Oliveira Guimarães da Silveira,

Verônica Palmiro da Silva e Lima,

Branca Dias Batista de Souza

Publication year - 2018

Publication title -

future science oa

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.825

H-Index - 23

ISSN - 2056-5623

DOI - 10.4155/fsoa-2018-0025

Subject(s) - abatacept , tocilizumab , medicine , rheumatoid arthritis , rituximab , biologic agents , biological drugs , retrospective cohort study , tofacitinib , lymphoma

Aim: To assess drug switching, rates of remission and disease activity in Brazilian patients with rheumatoid arthritis (RA) treated with biologic agents. Materials & methods: Using a retrospective method, a total of 94 adult patients were included. Results: Anti-TNF was the first choice therapy in 85 (90.4%) patients. After an average of 8 years of follow-up, 55 (59%) patients were taking anti-TNF, 18 (19%) abatacept, eight (9%) tocilizumab and 13 (14%) rituximab. In this period, 99 switches of biological therapy were registered in 55 patients. Conclusion: After 8 years of follow-up, 54% of the RA patients on biological therapy were still experiencing high or moderate activity despite established treatment, including switching between different biologic agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research